Hepatitis C virus (HCV) is a hepatotropic and lymphotropic virus, responsible for both chronic hepatitis and extra-hepatic manifestations. Multiple epidemiologic, clinical, biological, and molecular studies have suggested that HCV plays a causal role also in the development of several lymphoproliferative disorders, either benign, such as mixed cryoglobulinemia, or malignant, such as B-cell non-Hodgkin lymphomas (NHL). Chronic viral antigenic stimulation of B-lymphocytes plays a fundamental basic role from the on -set of lymphoma to its final steps. In the past, several studies demonstrated that the association of pe-gylated interferon plus ribavirin was able to eradicate HCV, with subsequent regression of indolent B-cell low-grade NHL. Other studies have demonstrated that direct antiviral agents (DAAs) therapy have some efficacy in HCV-associated NHL, particularly in patients with low-grade NHL or marginal zone-lymphoma, but these results need to be confirmed in larger studies with longer follow-up. The response rate of an-tiviral therapy seems favorable also in high grade NHL when DAAs therapy is administered in combina-tion with chemotherapy and therefore antiviral therapy should be considered as a first-line approach in HCV-related NHL.(c) 2022 Published by Elsevier Inc.

Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy

Gragnani, Laura;
2022-01-01

Abstract

Hepatitis C virus (HCV) is a hepatotropic and lymphotropic virus, responsible for both chronic hepatitis and extra-hepatic manifestations. Multiple epidemiologic, clinical, biological, and molecular studies have suggested that HCV plays a causal role also in the development of several lymphoproliferative disorders, either benign, such as mixed cryoglobulinemia, or malignant, such as B-cell non-Hodgkin lymphomas (NHL). Chronic viral antigenic stimulation of B-lymphocytes plays a fundamental basic role from the on -set of lymphoma to its final steps. In the past, several studies demonstrated that the association of pe-gylated interferon plus ribavirin was able to eradicate HCV, with subsequent regression of indolent B-cell low-grade NHL. Other studies have demonstrated that direct antiviral agents (DAAs) therapy have some efficacy in HCV-associated NHL, particularly in patients with low-grade NHL or marginal zone-lymphoma, but these results need to be confirmed in larger studies with longer follow-up. The response rate of an-tiviral therapy seems favorable also in high grade NHL when DAAs therapy is administered in combina-tion with chemotherapy and therefore antiviral therapy should be considered as a first-line approach in HCV-related NHL.(c) 2022 Published by Elsevier Inc.
2022
Mazzaro, Cesare; Bomben, Riccardo; Gragnani, Laura; Visentini, Marcella; Pozzato, Gabriele; Pozzo, Federico; Zucchetto, Antonella; Gattei, Valter
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/1172547
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact